Export translations
Jump to navigation
Jump to search
Settings
Group
Coil
ENDS Cardiovascular System
ENDS EVALI VALI THCVALI
ENDS Flavors
ENDS Positive study collection
ENDS Respiratory System
ENDS Taxes
ENDS The Fight to Abolish an Industry
ENDS Toxicity / Carcinogenic
ENDS Youth & Young Adults
Main Page
Mythbusters
Nicotine / THR - Change the Conversation
Nicotine / THR - Guides for Policymakers & Advocates
Nicotine / THR - Statements from Organizations
Nicotine Replacement Therapy
Nicotine Studies
Nicotine therapeutic benefits
Ohms law
Safer Nicotine Wiki:About
Safer Nicotine Wiki:Copyrights
Safer Nicotine Wiki:General disclaimer
Tobacco Harm Reduction News
Language
aa - Afar
aae - Arbëresh
ab - Abkhazian
abs - Ambonese Malay
ace - Achinese
acm - Iraqi Arabic
ady - Adyghe
ady-cyrl - Adyghe (Cyrillic script)
aeb - Tunisian Arabic
aeb-arab - Tunisian Arabic (Arabic script)
aeb-latn - Tunisian Arabic (Latin script)
af - Afrikaans
aln - Gheg Albanian
alt - Southern Altai
am - Amharic
ami - Amis
an - Aragonese
ang - Old English
ann - Obolo
anp - Angika
ar - Arabic
arc - Aramaic
arn - Mapuche
arq - Algerian Arabic
ary - Moroccan Arabic
arz - Egyptian Arabic
as - Assamese
ase - American Sign Language
ast - Asturian
atj - Atikamekw
av - Avaric
avk - Kotava
awa - Awadhi
ay - Aymara
az - Azerbaijani
azb - South Azerbaijani
ba - Bashkir
ban - Balinese
ban-bali - Balinese (Balinese script)
bar - Bavarian
bbc - Batak Toba
bbc-latn - Batak Toba (Latin script)
bcc - Southern Balochi
bci - Baoulé
bcl - Central Bikol
bdr - West Coast Bajau
be - Belarusian
be-tarask - Belarusian (Taraškievica orthography)
bew - Betawi
bg - Bulgarian
bgn - Western Balochi
bh - Bhojpuri
bho - Bhojpuri
bi - Bislama
bjn - Banjar
blk - Pa'O
bm - Bambara
bn - Bangla
bo - Tibetan
bpy - Bishnupriya
bqi - Bakhtiari
br - Breton
brh - Brahui
bs - Bosnian
btm - Batak Mandailing
bto - Iriga Bicolano
bug - Buginese
bxr - Russia Buriat
ca - Catalan
cbk-zam - Chavacano
cdo - Mindong
ce - Chechen
ceb - Cebuano
ch - Chamorro
chn - Chinook Jargon
cho - Choctaw
chr - Cherokee
chy - Cheyenne
ckb - Central Kurdish
co - Corsican
cps - Capiznon
cpx - Pu–Xian Min
cpx-hans - Pu–Xian Min (Simplified Han script)
cpx-hant - Pu–Xian Min (Traditional Han script)
cpx-latn - Pu–Xian Min (Latin script)
cr - Cree
crh - Crimean Tatar
crh-cyrl - Crimean Tatar (Cyrillic script)
crh-latn - Crimean Tatar (Latin script)
crh-ro - Dobrujan Tatar
cs - Czech
csb - Kashubian
cu - Church Slavic
cv - Chuvash
cy - Welsh
da - Danish
dag - Dagbani
de - German
de-at - Austrian German
de-ch - Swiss High German
de-formal - German (formal address)
dga - Dagaare
din - Dinka
diq - Zazaki
dsb - Lower Sorbian
dtp - Central Dusun
dty - Doteli
dv - Divehi
dz - Dzongkha
ee - Ewe
efi - Efik
egl - Emilian
el - Greek
eml - Emiliano-Romagnolo
en - English
en-ca - Canadian English
en-gb - British English
eo - Esperanto
es - Spanish
es-419 - Latin American Spanish
es-formal - Spanish (formal address)
et - Estonian
eu - Basque
ext - Extremaduran
fa - Persian
fat - Fanti
ff - Fula
fi - Finnish
fit - Tornedalen Finnish
fj - Fijian
fo - Faroese
fon - Fon
fr - French
frc - Cajun French
frp - Arpitan
frr - Northern Frisian
fur - Friulian
fy - Western Frisian
ga - Irish
gaa - Ga
gag - Gagauz
gan - Gan
gan-hans - Gan (Simplified Han script)
gan-hant - Gan (Traditional Han script)
gcf - Guadeloupean Creole
gcr - Guianan Creole
gd - Scottish Gaelic
gl - Galician
gld - Nanai
glk - Gilaki
gn - Guarani
gom - Goan Konkani
gom-deva - Goan Konkani (Devanagari script)
gom-latn - Goan Konkani (Latin script)
gor - Gorontalo
got - Gothic
gpe - Ghanaian Pidgin
grc - Ancient Greek
gsw - Alemannic
gu - Gujarati
guc - Wayuu
gur - Frafra
guw - Gun
gv - Manx
ha - Hausa
hak - Hakka Chinese
haw - Hawaiian
he - Hebrew
hi - Hindi
hif - Fiji Hindi
hif-latn - Fiji Hindi (Latin script)
hil - Hiligaynon
hno - Northern Hindko
ho - Hiri Motu
hr - Croatian
hrx - Hunsrik
hsb - Upper Sorbian
hsn - Xiang
ht - Haitian Creole
hu - Hungarian
hu-formal - Hungarian (formal address)
hy - Armenian
hyw - Western Armenian
hz - Herero
ia - Interlingua
ibb - Ibibio
id - Indonesian
ie - Interlingue
ig - Igbo
igl - Igala
ii - Sichuan Yi
ik - Inupiaq
ike-cans - Eastern Canadian (Aboriginal syllabics)
ike-latn - Eastern Canadian (Latin script)
ilo - Iloko
inh - Ingush
io - Ido
is - Icelandic
it - Italian
iu - Inuktitut
ja - Japanese
jam - Jamaican Creole English
jbo - Lojban
jut - Jutish
jv - Javanese
ka - Georgian
kaa - Kara-Kalpak
kab - Kabyle
kai - Karekare
kbd - Kabardian
kbd-cyrl - Kabardian (Cyrillic script)
kbp - Kabiye
kcg - Tyap
kea - Kabuverdianu
kg - Kongo
kge - Komering
khw - Khowar
ki - Kikuyu
kiu - Kirmanjki
kj - Kuanyama
kjh - Khakas
kjp - Eastern Pwo
kk - Kazakh
kk-arab - Kazakh (Arabic script)
kk-cn - Kazakh (China)
kk-cyrl - Kazakh (Cyrillic script)
kk-kz - Kazakh (Kazakhstan)
kk-latn - Kazakh (Latin script)
kk-tr - Kazakh (Turkey)
kl - Kalaallisut
km - Khmer
kn - Kannada
ko - Korean
ko-kp - Korean (North Korea)
koi - Komi-Permyak
kr - Kanuri
krc - Karachay-Balkar
kri - Krio
krj - Kinaray-a
krl - Karelian
ks - Kashmiri
ks-arab - Kashmiri (Arabic script)
ks-deva - Kashmiri (Devanagari script)
ksh - Colognian
ksw - S'gaw Karen
ku - Kurdish
ku-arab - Kurdish (Arabic script)
ku-latn - Kurdish (Latin script)
kum - Kumyk
kus - Kʋsaal
kv - Komi
kw - Cornish
ky - Kyrgyz
la - Latin
lad - Ladino
lb - Luxembourgish
lbe - Lak
lez - Lezghian
lfn - Lingua Franca Nova
lg - Ganda
li - Limburgish
lij - Ligurian
liv - Livonian
lki - Laki
lld - Ladin
lmo - Lombard
ln - Lingala
lo - Lao
loz - Lozi
lrc - Northern Luri
lt - Lithuanian
ltg - Latgalian
lus - Mizo
luz - Southern Luri
lv - Latvian
lzh - Literary Chinese
lzz - Laz
mad - Madurese
mag - Magahi
mai - Maithili
map-bms - Basa Banyumasan
mdf - Moksha
mg - Malagasy
mh - Marshallese
mhr - Eastern Mari
mi - Māori
min - Minangkabau
mk - Macedonian
ml - Malayalam
mn - Mongolian
mnc - Manchu
mnc-latn - Manchu (Latin script)
mnc-mong - Manchu (Mongolian script)
mni - Manipuri
mnw - Mon
mo - Moldovan
mos - Mossi
mr - Marathi
mrh - Mara
mrj - Western Mari
ms - Malay
ms-arab - Malay (Jawi script)
mt - Maltese
mus - Muscogee
mwl - Mirandese
my - Burmese
myv - Erzya
mzn - Mazanderani
na - Nauru
nah - Nāhuatl
nan - Minnan
nap - Neapolitan
nb - Norwegian Bokmål
nds - Low German
nds-nl - Low Saxon
ne - Nepali
new - Newari
ng - Ndonga
nia - Nias
nit - కొలామి
niu - Niuean
nl - Dutch
nl-informal - Dutch (informal address)
nmz - Nawdm
nn - Norwegian Nynorsk
no - Norwegian
nod - Northern Thai
nog - Nogai
nov - Novial
nqo - N’Ko
nrm - Norman
nso - Northern Sotho
nv - Navajo
ny - Nyanja
nyn - Nyankole
nyo - Nyoro
nys - Nyungar
oc - Occitan
ojb - Northwestern Ojibwa
olo - Livvi-Karelian
om - Oromo
or - Odia
os - Ossetic
pa - Punjabi
pag - Pangasinan
pam - Pampanga
pap - Papiamento
pcd - Picard
pcm - Nigerian Pidgin
pdc - Pennsylvania German
pdt - Plautdietsch
pfl - Palatine German
pi - Pali
pih - Norfuk / Pitkern
pl - Polish
pms - Piedmontese
pnb - Western Punjabi
pnt - Pontic
prg - Prussian
ps - Pashto
pt - Portuguese
pt-br - Brazilian Portuguese
pwn - Paiwan
qqq - Message documentation
qu - Quechua
qug - Chimborazo Highland Quichua
rgn - Romagnol
rif - Riffian
rki - Arakanese
rm - Romansh
rmc - Carpathian Romani
rmy - Vlax Romani
rn - Rundi
ro - Romanian
roa-tara - Tarantino
rsk - Pannonian Rusyn
ru - Russian
rue - Rusyn
rup - Aromanian
ruq - Megleno-Romanian
ruq-cyrl - Megleno-Romanian (Cyrillic script)
ruq-latn - Megleno-Romanian (Latin script)
rut - Rutul
rw - Kinyarwanda
ryu - Okinawan
sa - Sanskrit
sah - Yakut
sat - Santali
sc - Sardinian
scn - Sicilian
sco - Scots
sd - Sindhi
sdc - Sassarese Sardinian
sdh - Southern Kurdish
se - Northern Sami
se-fi - Northern Sami (Finland)
se-no - Northern Sami (Norway)
se-se - Northern Sami (Sweden)
sei - Seri
ses - Koyraboro Senni
sg - Sango
sgs - Samogitian
sh - Serbo-Croatian
sh-cyrl - Serbo-Croatian (Cyrillic script)
sh-latn - Serbo-Croatian (Latin script)
shi - Tachelhit
shi-latn - Tachelhit (Latin script)
shi-tfng - Tachelhit (Tifinagh script)
shn - Shan
shy - Shawiya
shy-latn - Shawiya (Latin script)
si - Sinhala
simple - Simple English
sjd - Kildin Sami
sje - Pite Sami
sk - Slovak
skr - Saraiki
skr-arab - Saraiki (Arabic script)
sl - Slovenian
sli - Lower Silesian
sm - Samoan
sma - Southern Sami
smn - Inari Sami
sms - Skolt Sami
sn - Shona
so - Somali
sq - Albanian
sr - Serbian
sr-ec - Serbian (Cyrillic script)
sr-el - Serbian (Latin script)
srn - Sranan Tongo
sro - Campidanese Sardinian
ss - Swati
st - Southern Sotho
stq - Saterland Frisian
sty - Siberian Tatar
su - Sundanese
sv - Swedish
sw - Swahili
syl - Sylheti
szl - Silesian
szy - Sakizaya
ta - Tamil
tay - Tayal
tcy - Tulu
tdd - Tai Nuea
te - Telugu
tet - Tetum
tg - Tajik
tg-cyrl - Tajik (Cyrillic script)
tg-latn - Tajik (Latin script)
th - Thai
ti - Tigrinya
tk - Turkmen
tl - Tagalog
tly - Talysh
tly-cyrl - Talysh (Cyrillic script)
tn - Tswana
to - Tongan
tok - Toki Pona
tpi - Tok Pisin
tr - Turkish
tru - Turoyo
trv - Taroko
ts - Tsonga
tt - Tatar
tt-cyrl - Tatar (Cyrillic script)
tt-latn - Tatar (Latin script)
ttj - Tooro
tum - Tumbuka
tw - Twi
ty - Tahitian
tyv - Tuvinian
tzm - Central Atlas Tamazight
udm - Udmurt
ug - Uyghur
ug-arab - Uyghur (Arabic script)
ug-latn - Uyghur (Latin script)
uk - Ukrainian
ur - Urdu
uz - Uzbek
uz-cyrl - Uzbek (Cyrillic script)
uz-latn - Uzbek (Latin script)
ve - Venda
vec - Venetian
vep - Veps
vi - Vietnamese
vls - West Flemish
vmf - Main-Franconian
vmw - Makhuwa
vo - Volapük
vot - Votic
vro - Võro
wa - Walloon
wal - Wolaytta
war - Waray
wls - Wallisian
wo - Wolof
wuu - Wu
wuu-hans - Wu (Simplified Han script)
wuu-hant - Wu (Traditional Han script)
xal - Kalmyk
xh - Xhosa
xmf - Mingrelian
xsy - Saisiyat
yi - Yiddish
yo - Yoruba
yrl - Nheengatu
yue - Cantonese
yue-hans - Cantonese (Simplified Han script)
yue-hant - Cantonese (Traditional Han script)
za - Zhuang
zea - Zeelandic
zgh - Standard Moroccan Tamazight
zh - Chinese
zh-cn - Chinese (China)
zh-hans - Simplified Chinese
zh-hant - Traditional Chinese
zh-hk - Chinese (Hong Kong)
zh-mo - Chinese (Macau)
zh-my - Chinese (Malaysia)
zh-sg - Chinese (Singapore)
zh-tw - Chinese (Taiwan)
zu - Zulu
Format
Export for off-line translation
Export in native format
Export in CSV format
Fetch
<languages/> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> '''Studies, Surveys, Papers, and Case Studies''' *Sometimes it's necessary to view the PDF version to access the full study. *This page is for referencing the possible benefits of [[Special:MyLanguage/Abbreviations|'''ENDS''']] products vs. smoking cigarettes from a Respiratory System standpoint. (Electronic Nicotine Delivery Systems are also known as vapor technology, ecigarettes, ecigs, EVP, etc.) *If you'd prefer someone else to add a study to a topic, there is a subject section called "Suggested studies to add to this page". You may put the link in that section for one of the regular page editors to address. *If you'd like to add content to this page, please see the instructions for editors at the bottom of the page. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> =Studies= </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2021: [https://www.sciencedirect.com/science/article/abs/pii/S2213260021000229 Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Use of an ENDS with cigarette-like nicotine delivery can reduce exposure to a major pulmonary carcinogen, NNAL, even with concurrent smoking. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://www.sciencedirect.com/science/article/abs/pii/S0306460319301832?via%3Dihub Benefits of e-cigarettes in smoking reduction and in pulmonary health among chronic smokers undergoing a lung cancer screening program at 6 months]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> The study is a double-blind randomized controlled trial. Two hundred and ten smokers were randomized into three groups: nicotine e-cigarette (8 mg/mL nicotine concentration), nicotine-free e-cigarettes (placebo), and control with 1:1:1 ratio. All participants received a 3 months cessation program that included a cognitive-behavioral intervention aimed at supporting people in changing their behavior and improving motivation to quit. After 6 months about 20% of the entire sample stopped smoking. Participants who used e-cigarettes with nicotine smoked fewer tobacco cigarettes than any other group after 6 months. Our data add to the efficacy and safety of e-cigarettes in helping smokers reducing tobacco consumption and improving pulmonary health status. Pulmonary health, assessed with self-reported measures, clinical evaluations and the Leicester Cough Questionnaire, improved in participants who stopped smoking compared to their own baseline. Moreover, participants in this group [nicotine e-cigarettes] showed the lowest level of exhaled carbon monoxide, and the lowest level of dependence compared to the nicotine-free e-cigarette and control conditions. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://www.nber.org/papers/w27507 E-Cigarettes and Respiratory Disease: A Replication, Extension, and Future Directions]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> *The statistical associations between e-cigarette use and respiratory disease are driven by e-cigarette users who are also current or former smokers of combustible tobacco. *A striking feature of the data is that almost all e-cigarette users were either current or former smokers of combustible tobacco. *Among respondents who had never smoked combustible tobacco, we find no evidence that current or former e-cigarette use is associated with respiratory disease. [https://www.nber.org/system/files/working_papers/w27507/w27507.pdf Link to PDF] <br> <br> </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://academic.oup.com/ntr/article/22/Supplement_1/S54/5893624?login=true Exclusive e-cigarette users report lower levels of respiratory symptoms relative to dual e-cigarette and cigarette users]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Findings suggest that differences in respiratory symptoms between dual and exclusive e-cigarette users appear to be attributable to combustible cigarette smoking, rather than more intense or frequent e-cigarette use across groups. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://pubmed.ncbi.nlm.nih.gov/32881666/ Investigation on the antibacterial activity of electronic cigarette liquids (ECLs): a proof of concept study]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> *Our results have shown that flavors considerably enhance antibacterial activity. *This study provides important evidence that should be taken into consideration in further investigative approaches, to clarify the different sensitivity of the various bacterial species to e-liquids, including the respiratory microbiota, to highlight the possible role of flavors and nicotine. *Citation: Virginia Fuochi, Massimo Caruso , Rosalia Emma, Aldo Stivala, Riccardo Polosa, Alfio Distefano and Pio Maria Furneri *, “Investigation on the Antibacterial Activity of Electronic Cigarette Liquids (ECLs): A Proof of Concept Study”, Current Pharmaceutical Biotechnology (2020) 21: 1. doi:10.2174/1389201021666200903121624 </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://www.medrxiv.org/content/10.1101/2020.10.21.20216630v1 SACCHARIN TRANSIT TIME IN EXCLUSIVE E-CIGARETTES AND HEATED TOBACCO PRODUCTS USERS: A CROSS-SECTIONAL STUDY]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Ex-smokers who have switched to exclusive regular use of combustion-free nicotine delivery systems (i.e. ECs/e-cigarettes and HTPs/heated tobacco products) exhibit similar saccharin transit time as never and former smokers. This suggests that combustion-free nicotine delivery technologies are unlikely to have detrimental effects on MCC (mucociliary clearance) function </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://journals.sagepub.com/doi/full/10.1177/2040622320961617 COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> The present study suggests that EC use may ameliorate objective and subjective COPD outcomes, and that the benefits gained appear to persist long term. EC use for abstinence and smoking reduction may ameliorate some of the harm resulting from tobacco smoking in COPD patients. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://link.springer.com/article/10.1007/s00204-020-02924-x Cancer potencies and margin of exposure used for comparative risk assessment of heated tobacco products (HTPs) and electronic cigarettes (ECs) aerosols with cigarette smoke]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> (PDF 16 pages) Even if they should not be considered as risk-free products, however, HTPs and ECs lead to an appreciable risk reduction in comparison to cigarettes, both for cancer and non-cancer diseases. According to the current knowledge, and more specifically to the data presented here, HTPs and ECs might be considered as an acceptable reduced risk substitute for cigarettes for legal-age smokers who would otherwise continue smoking cigarettes. A more pronounced cancer risk reduction was observed when comparing the mean lifetime cancer risk for the considered ECs with that for cigarette smoke. This reduction was about two orders of magnitude (ratio of 0.009 and 0.014) with 2.42·10–4 and 3.95·10–4 for ECs compared to 2.73·10–2 for cigarettes. In terms of consumers, this would mean that 1 out of 36 cigarette smokers vs. 1 out of 4132 or 1 out of 2531 EC consumers may develop a cancer if the cancer root cause would be only associated with exposure to the considered HPHCs. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2020: [https://pubmed.ncbi.nlm.nih.gov/31960343/ Vaping effects on asthma: results from a web survey and clinical investigation]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Almost all of the asthmatics who previously smoked would recommend switching to e-cig, and vaping did not worsen their asthma symptoms. Furthermore, switching from tobacco smoking to e-cigs showed a significant improvement in asthma control and quality of life, not showing, in the period studied, to affect pulmonary function tests. [https://sci-hub.se/10.1007/s11739-019-02247-5 PDF Version] </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2019: [https://www.tandfonline.com/doi/full/10.1080/17476348.2019.1649146 The effect of e-cigarette aerosol emissions on respiratory health: a narrative review].=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Expert opinion: There is growing evidence to support the relative safety of E-Cigarette (EC) emission aerosols for the respiratory tract compared to tobacco smoke. Public Health England estimated, on the basis of a review of 185 studies, that vaping an e-cigarette is likely to be at least 95% less harmful than smoking a regular cigarette. In 2016, the Royal College of Physicians reaffirmed this figure, estimating the risk of long-term inhalation of e-cigarette aerosol to be unlikely to exceed 5% of the risk associated with long-term cigarette smoking. This review article shows that although some potential effects on respiratory cell types can be shown in vitro, and low levels of chronic irritation of the respiratory tract can be anticipated at certain levels of vaping, these effects are much less than those of smoking. The clinical evidence confirms that ECs are unlikely to raise significant health concerns for the respiratory tract under normal conditions of use. Former smokers using and smokers intending to use ECs as a substitute for smoking should receive correct information about residual risks and potential benefits of these products. Promoting further access to ECs may offer an opportunity to reduce or prevent some of the otherwise inevitable burden of respiratory morbidity and mortality caused by tobacco smoking In an Expert Review in Respiratory Medicine article published about 7 years ago [Caponnetto P, Campagna D, Papale G, et al. The emerging phenomenon of electronic cigarettes. Expert Rev Respir Med. 2012 Feb; 6(1):63–74.., we discussed several important research developments and future avenues for e-cigarette science. In the authors’ view, those expert opinions have been substantiated by the growing body of evidence. We therefore reiterate our prediction that EC use is the most effective method of substituting tobacco cigarettes for those smokers who are unable or unwilling to quit and we are now confident that current vaping products are much less harmful than conventional cigarettes as well as earlier EC designs. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2018: [https://www.dovepress.com/health-effects-in-copd-smokers-who-switch-to-electronic-cigarettes-a-r-peer-reviewed-fulltext-article-COPD Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> The present study suggests that EC use may ameliorate objective and subjective COPD outcomes and that the benefits gained may persist long-term. EC use may reverse some of the harm resulting from tobacco smoking in COPD patients </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017: [https://www.nature.com/articles/s41598-017-14043-2?fbclid=IwAR1YUw7H95R1mAOuD6JcjsQG3Kl6-qtdbzp2s2zx9UnJGn_w79VcnkpE2kY Health impact of E-cigarettes: a prospective 3.5-year study of regular daily users who have never smoked]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> In a small sample of young-adult never-smoking, daily EC users who were carefully followed for approximately 3½ years, we found no decrements in spirometric indices, development of respiratory symptoms, changes in markers of lung inflammation in exhaled air or findings of early lung damage on HRCT, when compared with a carefully matched group of never-smoking non-EC users. Even the heaviest EC users failed to exhibit any evidence of emerging lung injury as reflected in these physiologic, clinical or inflammatory measures. Moreover, no changes were noted in blood pressure or heart rate. Since the EC users who we studied were never smokers, potential confounding by inhalation of combustion products of tobacco were obviated. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017: [https://www.dovepress.com/e-cigarettes-in-patients-with-copd-current-perspectives-peer-reviewed-fulltext-article-COPD E-cigarettes in patients with COPD: current perspectives]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Although ECs are not risk free, they are much less harmful than conventional tobacco smoking. The emerging clinical evidence suggests that ECs are unlikely to raise significant health concerns for the respiratory tract under normal conditions of use, even in smokers with preexisting lung disease. In particular, recent studies in COPD and chronic asthma suggest that substitution of conventional tobacco cigarettes for ECs can ameliorate subjective and objective disease-related outcomes and exacerbation rates as well as improving success in abstaining from smoking long term. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429854/ Reduced biological effect of e-cigarette aerosol compared to cigarette smoke evaluated in vitro using normalized nicotine dose and RNA-seq-based toxicogenomics]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Here, we assessed the transcriptional response of a primary 3D airway model acutely exposed to e-cigarette aerosol and cigarette (3R4F) smoke. Based on equivalent or higher nicotine delivery, an acute exposure to e-cigarette aerosol had a reduced impact on gene expression compared to 3R4F smoke exposure in vitro. Therefore, we can conclude that the data strongly supports the adverse effect of acute exposure to cigarette smoke on MucilAir™ cells with functional enrichment for cancer, inflammation and fibrosis genes. In contrast, RNA-seq-based toxicogenomics showed a reduced impact of e-cigarette aerosols acute exposure on MucilAir™ cells compared with 3R4F reference cigarette at equivalent or higher dose of nicotine exposure. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017: [https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-017-0676-9 Electronic cigarette vapor alters the lateral structure but not tensiometric properties of calf lung surfactant]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> While both e-cigarette vapor and conventional cigarette smoke affect surfactant lateral structure, only cigarette smoke disrupts surfactant interfacial properties. The surfactant inhibitory compound in conventional cigarettes is tar, which is a product of burning and is thus absent in e-cigarette vapor. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017: [https://tobaccocontrol.bmj.com/content/27/1/10 Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> (PDF 8 pages) “Most e-cigarette analyses indicate cancer potencies <1% that of tobacco smoke and <10% that of a heat-not-burn prototype, although a minority of analyses indicate higher potencies.” Optimal combinations of device settings, liquid formulation and vaping behaviour normally result in e-cigarette emissions with much less carcinogenic potency than tobacco smoke. Article in Lung Disease News: [https://lungdiseasenews.com/2017/08/25/study-finds-that-cancer-risk-of-e-cigarettes-is-much-lower-than-that-of-cigarette-smoke/?fbclid=IwAR1qEBP2dW4ccXc0fUEWpZIR6ZpsBJwMw-tDsB_PFiiHgR4XaJRaIAbutl4 E-Cigarettes Carry Much Less Risk of Lung Cancer Than Cigarette Smoke, Study Finds] </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017: [https://tobaccocontrol.bmj.com/content/26/e1/e23.long Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation (G2) and third-generation (G3) electronic cigarette user]s=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> (PDF 6 pages) While not harmless, electronic cigarettes (e-cigarettes) have demonstrated a much more favourable toxicological profile than combustible cigarettes—the worldwide leading cause of preventable death. Average eCO levels (ppm) were significantly higher in smokers than in e-cigarette users. Compared with cigarettes, G2 and G3 e-cigarettes resulted in significantly lower levels of exposure to a potent lung carcinogen and cardiovascular toxicant. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2016: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5162097/ Evidence for harm reduction in COPD smokers who switch to electronic cigarettes] (EC’s)=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Conclusion: “These findings suggest that ECs use may aid smokers with COPD reduce their cigarette consumption or remain abstinent, which results in marked improvements in annual exacerbation rate as well as subjective and objective COPD outcomes.” </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2016: [https://www.omicsonline.org/open-access/changes-in-the-frequency-of-airway-infections-in-smokers-who-switched-to-vaping-results-of-an-online-survey-2155-6105-1000290.pdf Changes in the Frequency of Airway Infections in Smokers Who Switched to Vaping: Results of an Online Survey]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Results: “Altogether 941 responses were received. Overall, 29% of responders reported no change in respiratory symptoms, 5% reported worsening, and 66% reported an improvement (95% CI=62.9-69.0).” </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2016: [https://pubmed.ncbi.nlm.nih.gov/27011045/ Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> This prospective study confirms that EC use ameliorates objective and subjective asthma outcomes and shows that these beneficial effects may persist in the long term. EC use can reverse harm from tobacco smoking in asthma patients who smoke. The evidence-based notion that substitution of conventional cigarettes with EC is unlikely to raise significant respiratory concerns, can improve counseling between physicians and their asthmatic patients who are using or intend to use ECs. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2016: [https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.12651 Changes in breathomics from a 1‐year randomized smoking cessation trial of electronic cigarettes]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Conclusion: “Smokers invited to switch to electronic cigarettes who completely abstained from smoking showed steady progressive improvements in their exhaled breath measurements and symptom scores. FeNo and eCO normalization is highly supportive of improved respiratory health outcomes and adds to the notion that quitting from tobacco smoking can reverse harm in the lung.” </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2016: [https://www.omicsonline.org/open-access/changes-in-the-frequency-of-airway-infections-in-smokers-who-switched-to-vaping-results-of-an-online-survey-2155-6105-1000290.php?aid=77944 Changes in the Frequency of Airway Infections in Smokers Who Switched To Vaping: Results of an Online Survey]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> The switch from smoking to vaping was associated with a reduced incidence of self-reported respiratory infections. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2016: [https://pneumonia.biomedcentral.com/articles/10.1186/s41479-016-0001-2 Respiratory infections and pneumonia: potential benefits of switching from smoking to Vaping]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Also, given that the propylene glycol in EC aerosols is a potent bactericidal agent, switching from smoking to regular vaping is likely to produce additional lung health benefits. In conclusion, smokers who quit by switching to regular ECs use can reduce risk and reverse harm from tobacco smoking. Innovation in the e-vapour category is likely not only to further minimise residual health risks, but also to maximise health benefits. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2016: [https://www.lungcancerjournal.info/article/S0169-5002(16)30323-3/fulltext Patients with lung cancer: Are electronic cigarettes harmful or useful?]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> (must pay to view PDF) Based on current knowledge, for patients with lung or other forms of cancer who would otherwise continue to smoke, e-cigarettes offer an alternative way to quit smoking while they undergo medical treatment. The option to switch to e-cigarettes should be considered by healthcare practitioners with patients with cancer who would otherwise continue to smoke. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2014: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053879/ Effect of Smoking Abstinence and Reduction in Asthmatic Smokers Switching to Electronic Cigarettes: Evidence for Harm Reversal]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> The e-cig may help smokers with asthma to reduce their cigarette consumption or remain abstinent and hence reduce the burden of smoking-related asthma symptoms. The positive findings observed with e-cigs allows us to advance the hypothesis that these products may be valuable for smoking cessation and/or tobacco harm reduction also in asthma patients who smoke. By substantially reducing number of cigarettes smoked per day and exposure to their hazardous toxicants, e-cigs may not only improve asthma symptoms and pulmonary function but may also confer an overall health advantage in smokers with asthma [13]. Therefore, e-cig use in asthmatic smokers unable or unwilling to quit should be exploited as a safer alternative approach to harm-reversal (i.e., specific reversal of asthma-related outcomes) and, in general, to harm-reduction (i.e., overall reduction of smoke-related diseases). </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> =Video= </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2021: [https://www.youtube.com/watch?v=7PT1TRo3b4M Vaping Demystified]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Yorkshire Cancer Research Through research and interviews with experts, we explore the truth about vaping and whether misconceptions are preventing us from reducing the largest preventable cause of cancer in Yorkshire. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> =2nd Hand Vapor= </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2018: [https://academic.oup.com/ntr/article/21/10/1371/5040053 Characterization of the Spatial and Temporal Dispersion Differences Between Exhaled E-Cigarette Mist and Cigarette Smoke]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> For both product categories, the particle concentrations registered following each puff were in the same order of magnitude. However, for e-cigarettes the particle concentration returned rapidly to background values within seconds; for conventional cigarettes it increased with successive puffs, returning to background levels after 30–45 minutes. Unlike for the e-cigarette devices tested, such temporal variation was dependent on the room ventilation rate. Particle size measurements showed that exhaled e-cigarette particles were smaller than those emitted during smoking conventional cigarettes and evaporated almost immediately after exhalation, thus affecting the removal of particles through evaporation rather than displacement by ventilation. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017 [https://www.cdc.gov/niosh/hhe/reports/pdfs/2015-0107-3279.pdf?fbclid=IwAR37EOr5p5EwptMhuyrIwEDkfi4qbMh0nRwu6yz2VkY0Um-q138f3LfK64Y Evaluation of Chemical Exposures at a Vape Shop]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> *We collected air samples for flavoring chemicals (diacetyl, 2,3-pentanedione, 2,3-hexanedione, acetaldehyde, and acetoin), nicotine, formaldehyde, and propylene glycol. *Concentrations of vaping-related chemicals in our air samples were below occupational exposure limits. *Citation: NIOSH 2017. Evaluation of chemical exposures at a vape shop. By Zwack LM, Stefaniak AB, LeBouf RF. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Health Hazard Evaluation Report [tel:2015-0107-3279 2015-0107-3279] </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2017 Dr. Michael Siegel - [http://tobaccoanalysis.blogspot.com/2017/05/vape-shop-air-sampling-by-california.html Vape Shop Air Sampling by California State Health Department Suggests that Second Hand Vape Exposure is Minimal]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> This study, although conducted under very high exposure conditions in a small, non-ventilated vape shop with many employees and customers vaping and clouds of vapor visible, did not document any dangerous levels of exposure to any hazardous chemical. Nicotine exposure was essentially non-existent. Formaldehyde exposure was no different than in many indoor and outdoor environments at baseline. Acetone, acetoin, other aldehydes, toluene, benzene, and xylene were not detected. Chemicals that have been associated with "popcorn lung" were also not detected by the standard method. This study adds to the evidence that under real-life conditions, "secondhand vaping" does not appear to pose any significant health risks. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2014: [https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-18 Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Threshold Limit Values (TLVs), were conducted under “worst case” assumptions about both chemical content of aerosol and liquids as well as behavior of vapers. There was no evidence of potential for exposures of e-cigarette users to contaminants that are associated with risk to health at a level that would warrant attention if it were an involuntary workplace exposures. Exposures of bystanders are likely to be orders of magnitude less, and thus pose no apparent concern. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> ===2012: [https://www.tandfonline.com/doi/abs/10.3109/08958378.2012.724728?scroll=top&needAccess=true&journalCode=iiht20 Comparison of the effects of e-cigarette vapor and cigarette smoke on indoor air quality]=== </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> Comparisons of pollutant concentrations were made between e-cigarette vapor and tobacco smoke samples. Pollutants included VOCs, carbonyls, PAHs, nicotine, TSNAs, and glycols. Non-cancer risk analysis revealed “No Significant Risk” of harm to human health for vapor samples from e-liquids. With regard to cancer risk analysis, no vapor sample from e-liquids exceeded the risk limit for either children or adults. </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> =PAGE EDITORS - Please add Studies, Surveys, Papers in this format to keep page organized= *Topic *Year (list new to old) Name of Study (In link format to the study) *Note here if animal study (leave blank if not) *Brief Summary *Link to PDF Version *Citation *Acknowledgements (funded by, helped by) *Keywords *Other </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> =Suggested studies to add to this page= </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> https://pubs.acs.org/doi/10.1021/acs.chemrestox.1c00253 </div> <div lang="en-GB" dir="ltr" class="mw-content-ltr"> =More Information= *Click on the category link below for more studies by topic on ENDS and Nicotine. [[Category:Studies, Surveys, and Papers]] </div>
Cookies help us deliver our services. By using our services, you agree to our use of cookies.
More information
OK
Navigation menu
Personal tools
British English
Create account
Log in
Namespaces
Translate
British English
Views
Language statistics
Message group statistics
Export
More
Refresh
Search
Navigation
Main page
All Pages
Recent changes
Random page
Help about MediaWiki
Main Categories
Latest News
Latest news on THR, Vaping and Safer Nicotine
Get involved
How To Edit safernicotine.wiki
Create an account
Translate pages
Translator Signup
Upload Multiple Files (Upload Wizard)
Tools
Special pages
Printable version